Autism spectrum disorder in the genetics clinic: A review

Clinical Genetics

Volumn 83, Issue 5, 2013, Pages 399-407

  Carter, Melissa T ^a   Scherer, S W ^b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Autism spectrum disorder; Copy number variant; Diagnosis; Genetic testing; Microarray; Synapse

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; METHYL CPG BINDING PROTEIN 2; NEUREXIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN PATCHED 1;

ABDOMINAL CRAMP; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BECKER MUSCULAR DYSTROPHY; BIOTINIDASE DEFICIENCY; BLOATING; BODY SIZE; BRAIN DEVELOPMENT; CHROMOSOME 15; CLINICAL FEATURE; CLINICAL GENETICS; COMORBIDITY; CONGENITAL MALFORMATION; CONSTIPATION; COWDEN SYNDROME; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL EXPOSURE; EPILEPSY; FAMILY HISTORY; FEEDING BEHAVIOR; FOOT MALFORMATION; FRAGILE X SYNDROME; FRYNS SYNDROME; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE SEQUENCE; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; HAPPY PUPPET SYNDROME; HEAD CIRCUMFERENCE; HIGH RISK INFANT; HUMAN; HYPERACTIVITY; HYPERSENSITIVITY; HYPOALGESIA; INFANTILE SPASM; INTELLECTUAL IMPAIRMENT; LANGUAGE DISABILITY; LEARNING DISORDER; LIPOFUSCINOSIS; LONG PHILTRUM; LYSOSOME STORAGE DISEASE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MENTAL DISEASE; MOLECULAR DIAGNOSIS; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NEUROLOGIC EXAMINATION; PHENOTYPE; PHYSICAL EXAMINATION; POSTSYNAPTIC DENSITY; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; RECURRENCE RISK; RETT SYNDROME; SCHIZOPHRENIA; SIMPSON GOLABI BEHMEL SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; SMITH LEMLI OPITZ SYNDROME; SOTOS SYNDROME; SYNDACTYLY; SYNDROME CHARGE; WILLIAMS BEUREN SYNDROME;

CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHROMOSOME ABERRATIONS; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MICROARRAY ANALYSIS; MUTATION; PTEN PHOSPHOHYDROLASE; RECURRENCE;

EID: 84875898947     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12101     Document Type: Article

References (91)

1. State MW, Sestan N. Neuroscience. The emerging biology of autism spectrum disorders. Science 2012: 337 (6100): 1301-1303.
2. Devlin B, Scherer SW. Genetic architecture in autism spectrum disorder. Curr Opin Genet Dev 2012: 22(3): 229-237.
3. Mendelsohn NJ, Schaefer GB. Genetic evaluation of autism. Semin Pediatr Neurol 2008: 15 (1): 27-31.
4. Schiff M, Benoist JF, Aissaoui S et al. Should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders? PLoS One 2011: 6 (7): e21932.
5. Herman GE, Henninger N, Ratliff-Schaub K, Pastore M, Fitzgerald S, McBride KL. Genetic testing in autism: how much is enough? Genetics in medicine : official journal of the American College of Medical Genetics 2007: 9 (5): 268-274.
6. Miles JH. Autism spectrum disorders--a genetics review. Genet Med 2011: 13 (4): 278-294.
7. Johnson CP, Myers SM. Identification and evaluation of children with autism spectrum disorders. Pediatrics 2007: 120 (5): 1183-1215.
8. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. J Med Genet 2009: 46 (1): 1-8.
9. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet Med 2008: 10 (1): 4-12.
10. Miller DT, Adam MP, Aradhya S et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010: 86 (5): 749-764.
11. Shen Y, Dies KA, Holm IA et al. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics 2010: 125 (4): e727-e735.
12. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010: 12 (11): 742-745.
13. Marshall CR, Noor A, Vincent JB et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 2008: 82 (2): 477-488.
14. Pinto D, Pagnamenta AT, Klei L et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature 2010: 466 (7304): 368-372.
15. Sebat J, Lakshmi B, Malhotra D et al. Strong association of de novo copy number mutations with autism. Science 2007: 316 (5823): 445-449.
16. Sanders SJ, Ercan Sencicek AG, Hus V et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron 2011: 70 (5): 863-885.
17. Cook EH Jr, Lindgren V, Leventhal BL et al. Autism or atypical autism in maternally but not paternally derived proximal 15q duplication. Am J Hum Genet 1997: 60 (4): 928-934.
18. Battaglia A. The inv dup (15) or idic (15) syndrome (Tetrasomy 15q). Orphanet J Rare Dis 2008: 3: 30.
19. Bolton PF, Dennis NR, Browne CE et al. The phenotypic manifestations of interstitial duplications of proximal 15q with special reference to the autistic spectrum disorders. Am J Med Genet 2001: 105 (8): 675-685.
20. McCarthy SE, Makarov V, Kirov G et al. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet 2009: 41 (11): 1223-1227.
21. Shinawi M, Liu P, Kang SH et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioural problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 2010: 47 (5): 332-341.
22. Rosenfeld JA, Coppinger J, Bejjani BA et al. Speech delays and behavioral problems are the predominant features in individuals with developmental delays and 16p11.2 microdeletions and microduplications. J Neurodev Disord 2010: 2 (1): 26-38.
23. Jacquemont S, Reymond A, Zufferey F et al. Mirror extreme BMI phenotypes associated with gene dosage at the chromosome 16p11.2 locus. Nature 2011: 478 (7367): 97-102.
24. Philip N, Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. Behav Genet 2011: 41 (3): 403-412.
25. Vorstman JA, Morcus ME, Duijff SN et al. The 22q11.2 deletion in children: high rate of autistic disorders and early onset of psychotic symptoms. J Am Acad Child Adolesc Psychiatry 2006: 45 (9): 1104-1113.
26. Mukaddes NM, Herguner S. Autistic disorder and 22q11.2 duplication. World J Biol Psychiatry 2007: 8 (2): 127-130.
27. Moreno-De-Luca D, Sanders SJ, Willsey AJ et al. Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatry 2012. Epub 9 October 2012.
28. Courtens W, Schramme I, Laridon A. Microduplication 22q11.2: a benign polymorphism or a syndrome with a very large clinical variability and reduced penetrance?-report of two families. Am J Med Genet A 2008: 146A (6): 758-763.
29. Somerville MJ, Mervis CB, Young EJ et al. Severe expressive-language delay related to duplication of the Williams-Beuren locus. N Engl J Med 2005: 353 (16): 1694-1701.
30. Berg JS, Brunetti-Pierri N, Peters SU et al. Speech delay and autism spectrum behaviors are frequently associated with duplication of the 7q.1123 Williams-Beuren syndrome region. Genet Med 2007: 9 (7): 427-441.
31. Van der Aa N, Rooms L, Vandeweyer G et al. Fourteen new cases contribute to the characterization of the 7q11.23 microduplication syndrome. Eur J Med Genet 2009: 52 (2-3): 94-100.
32. Merla G, Brunetti-Pierri N, Micale L, Fusco C. Copy number variants at Williams-Beuren syndrome 7q11.23 region. Hum Genet 2010: 128 (1): 3-26.
33. Brunetti-Pierri N, Berg JS, Scaglia F et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008: 40 (12): 1466-1471.
34. Mefford HC, Sharp AJ, Baker C et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008: 359 (16): 1685-1699.
35. Sahoo T, Theisen A, Rosenfeld JA et al. Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. Genet Med 2011: 13 (10): 868-880.
36. Stefansson H, Rujescu D, Cichon S et al. Large recurrent microdeletions associated with schizophrenia. Nature 2008: 455 (7210): 232-236.
37. Brown WT, Jenkins EC, Friedman E et al. Autism is associated with the fragile-X syndrome. J Autism Dev Disord 1982: 12 (3): 303-308.
38. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 2007: 37 (4): 738-747.
39. Harris SW, Hessl D, Goodlin-Jones B et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008: 113 (6): 427-438.
40. Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 2001: 22 (6): 409-417.
41. Kaufmann WE, Cortell R, Kau AS et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A 2004: 129A (3): 225-234.
42. Cohen IL, Nolin SL, Sudhalter V, Ding XH, Dobkin CS, Brown WT. Mosaicism for the FMR1 gene influences adaptive skills development in fragile X-affected males. Am J Med Genet 1996: 64 (2): 365-369.
43. McConkie-Rosell A, Lachiewicz AM, Spiridigliozzi GA et al. Evidence that methylation of the FMR-I locus is responsible for variable phenotypic expression of the fragile X syndrome. Am J Hum Genet 1993: 53 (4): 800-809.
44. Bourdon V, Philippe C, Labrune O, Amsallem D, Arnould C, Jonveaux P. A detailed analysis of the MECP2 gene: prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients. Hum Genet 2001: 108 (1): 43-50.
45. Neul JL, Kaufmann WE, Glaze DG et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol 2010: 68 (6): 944-950.
46. Carney RM, Wolpert CM, Ravan SA et al. Identification of MeCP2 mutations in a series of females with autistic disorder. Pediatr Neurol 2003: 28 (3): 205-211.
47. Beyer KS, Blasi F, Bacchelli E, Klauck SM, Maestrini E, Poustka A. Mutation analysis of the coding sequence of the MECP2 gene in infantile autism. Hum Genet 2002: 111 (4-5): 305-309.
48. Vourch P, Bienvenu T, Beldjord C et al. No mutations in the coding region of the Rett syndrome gene MECP2 in 59 autistic patients. Eur J Hum Genet 2001: 9 (7): 556-558.
49. Villard L. MECP2 mutations in males. J Med Genet 2007: 44 (7): 417-423.
50. Coutinho AM, Oliveira G, Katz C et al. MECP2 coding sequence and 3'UTR variation in 172 unrelated autistic patients. Am J Med Genet B Neuropsychiatr Genet 2007: 144B (4): 475-483.
51. Shibayama A, Cook EH Jr, Feng J et al. MECP2 structural and 3'-UTR variants in schizophrenia, autism and other psychiatric diseases: a possible association with autism. Am J Med Genet B Neuropsychiatr Genet 2004: 128B (1): 50-53.
52. Ramocki MB, Peters SU, Tavyev YJ et al. Autism and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome. Ann Neurol 2009: 66 (6): 771-782.
53. Conti S, Condo M, Posar A et al. Phosphatase and tensin homolog (PTEN) gene mutations and autism: literature review and a case report of a patient with Cowden syndrome, autistic disorder, and epilepsy. J Child Neurol 2012: 27 (3): 392-397.
54. Varga EA, Pastore M, Prior T, Herman GE, McBride KL. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. Genet Med 2009: 11 (2): 111-117.
55. Buxbaum JD, Cai G, Chaste P et al. Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Neuropsychiatr Genet 2007: 144B (4): 484-491.
56. Mercer L, Creighton S, Holden JJ, Lewis ME. Parental perspectives on the causes of an autism spectrum disorder in their children. J Genet Couns 2006: 15 (1): 41-50.
57. Whitelaw C, Flett P, Amor DJ. Recurrence risk in autism spectrum disorder: a study of parental knowledge. J Paediatr Child Health 2007: 43 (11): 752-754.
58. Selkirk CG, McCarthy Veach P, Lian F, Schimmenti L, LeRoy BS. Parents' perceptions of autism spectrum disorder etiology and recurrence risk and effects of their perceptions on family planning: Recommendations for genetic counselors. J Genet Couns 2009: 18 (5): 507-519.
59. Vande Wydeven K, Kwan A, Hardan AY, Bernstein JA. Underutilization of genetics services for autism: the importance of parental awareness and provider recommendation. J Genet Couns 2012: 21(6): 803-813.
60. Ritvo ER, Jorde LB, Mason-Brothers A et al. The UCLA-University of Utah epidemiologic survey of autism: recurrence risk estimates and genetic counseling. Am J Psychiatry 1989: 146 (8): 1032-1036.
61. Jorde LB, Mason-Brothers A, Waldmann R et al. The UCLA-University of Utah epidemiologic survey of autism: genealogical analysis of familial aggregation. Am J Med Genet 1990: 36 (1): 85-88.
62. Ozonoff S, Young GS, Carter A et al. Recurrence risk for autism spectrum disorders: a Baby Siblings Research Consortium study. Pediatrics 2011: 128 (3): e488-e495.
63. Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001: 2 (12): 943-955.
64. Carter MT, Nikkel SM, Fernandez BA et al. Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder. Clin Genet 2011: 80 (5): 435-443.
65. O'Roak BJ, Vives L, Girirajan S et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 2012: 485 (7397): 246-250.
66. Neale BM, Kou Y, Liu L et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 2012: 485 (7397): 242-245.
67. Iossifov I, Ronemus M, Levy D et al. De novo gene disruptions in children on the autistic spectrum. Neuron 2012: 74 (2): 285-299.
68. Sanders SJ, Murtha MT, Gupta AR et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature 2012: 485 (7397): 237-241.
69. Noor A, Whibley A, Marshall CR et al. Disruption at the PTCHD1 Locus on Xp22.11 in autism spectrum disorder and intellectual disability. Sci Transl Med 2010: 2 (49): 49ra68.
70. Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature 2008: 455 (7215): 903-911.
71. Wisniowiecka-Kowalnik B, Nesteruk M, Peters SU et al. Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder, developmental delay, and speech delay. Am J Med Genet B Neuropsychiatr Genet 2010: 153B (5): 983-993.
72. Ching MS, Shen Y, Tan WH et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet 2010: 153B (4): 937-947.
73. Kim HG, Kishikawa S, Higgins AW et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet 2008: 82 (1): 199-207.
74. Szatmari P, Paterson AD, Zwaigenbaum L et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet 2007: 39 (3): 319-328.
75. Muhleisen TW, Basmanav FB, Forstner AJ et al. Resequencing and follow-up of neurexin 1 (NRXN1) in schizophrenia patients. Schizophr Res 2011: 127 (1-3): 35-40.
76. Rujescu D, Ingason A, Cichon S et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet 2009: 18 (5): 988-996.
77. Kirov G, Gumus D, Chen W et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet 2008: 17 (3): 458-465.
78. Walsh T, McClellan JM, McCarthy SE et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 2008: 320 (5875): 539-543.
79. Ikeda M, Aleksic B, Kirov G et al. Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry 2010: 67 (3): 283-286.
80. Griswold AJ, Ma D, Cukier HN et al. Evaluation of copy number variations reveals novel candidate genes in autism spectrum disorder-associated pathways. Hum Mol Genet 2012: 21 (15): 3513-3523.
81. Vaags AK, Lionel AC, Sato D et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. Am J Hum Genet 2012: 90 (1): 133-141.
82. Wilson HL, Wong AC, Shaw SR et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003: 40 (8): 575-584.
83. Dhar SU, del Gaudio D, German JR et al. 22q13.3 deletion syndrome: clinical and molecular analysis using array CGH. Am J Med Genet A 2010: 152A (3): 573-581.
84. Sarasua SM, Dwivedi A, Boccuto L et al. Association between deletion size and important phenotypes expands the genomic region of interest in Phelan-McDermid syndrome (22q13 deletion syndrome). J Med Genet 2011: 48 (11): 761-766.
85. Manning MA, Cassidy SB, Clericuzio C et al. Terminal 22q deletion syndrome: a newly recognized cause of speech and language disability in the autism spectrum. Pediatrics 2004: 114 (2): 451-457.
86. Durand CM, Betancur C, Boeckers TM et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet 2007: 39 (1): 25-27.
87. Moessner R, Marshall CR, Sutcliffe JS et al. Contribution of SHANK3 mutations to autism spectrum disorder. Am J Hum Genet 2007: 81 (6): 1289-1297.
88. Gauthier J, Spiegelman D, Piton A et al. Novel de novo SHANK3 mutation in autistic patients. Am J Med Genet B Neuropsychiatr Genet 2009: 150B (3): 421-424.
89. Waga C, Okamoto N, Ondo Y et al. Novel variants of the SHANK3 gene in Japanese autistic patients with severe delayed speech development. Psychiatr Genet 2011: 21 (4): 208-211.
90. Sato D, Lionel AC, Leblond CS et al. SHANK1 deletions in males with autism spectrum disorder. Am J Hum Genet 2012: 90 (5): 879-887.
91. Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, Pantelis C. Predicting the diagnosis of autism spectrum disorder using gene pathway analysis. Mol Psychiatry 2012. Epub 11 September 2012.